About Elektrofi
Elektrofi is a company based in Boston (United States) founded in 2016 by Chase Coffman and Jason Norris was acquired by Halozyme in October 2025. Elektrofi has raised $152.25 million across 4 funding rounds from investors including Lilly, Halozyme and Royalty Pharma. The company has 71 employees as of December 31, 2023. Elektrofi offers products and services including Hypercon Platform. Elektrofi operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and ProteinSimple, among others.
- Headquarter Boston, United States
- Employees 71 as on 31 Dec, 2023
- Founders Chase Coffman, Jason Norris
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Elektrofi, Inc.,
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Elektrofi
Elektrofi offers a comprehensive portfolio of products and services, including Hypercon Platform.
Enables hyper-concentrated microparticle delivery of biologic therapies subcutaneously
People of Elektrofi
Unlock access to complete
Funding Insights of Elektrofi
Elektrofi has successfully raised a total of $152.25M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $112.25 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Elektrofi
Elektrofi has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Halozyme and Royalty Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Locked | Locked | Locked | |
|
A biotechnology venture capital firm investing in innovative science.
|
Locked | Locked | Locked |
Investor details for Elektrofi
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Elektrofi
Investment portfolio details for Elektrofi
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Elektrofi
Detailed financials for Elektrofi
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Elektrofi Comparisons
Peer comparison for Elektrofi
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Elektrofi
Elektrofi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and ProteinSimple, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
Detailed competitors of Elektrofi
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Elektrofi
Complete news archive for Elektrofi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elektrofi
Elektrofi was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Elektrofi is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Chase Coffman is the current CEO of Elektrofi. They have also founded this company.
Elektrofi is a funded company, having raised a total of $152.25M across 4 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Elektrofi is 71.
Elektrofi was founded in 2016 and is headquartered in Boston, United States. Operations focus on the biotechnology sector, where a digital platform is employed to advance the administration of biologic medicines. Proprietary Hypercon microparticle technology is integrated to formulate concentrated biologic drugs, allowing treatments to be delivered through straightforward subcutaneous injections rather than traditional methods.
Elektrofi's top competitors include Somalogic, Nautilus Biotechnology and Biognosys.
Elektrofi offers Hypercon Platform.
Elektrofi has 12 investors. Key investors include Lilly, Halozyme, Royalty Pharma, TPG, and Marshall Wace.